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INTRODUCTION
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Pneumonia is an important cause of morbidity, mortality and expenditure of health resources. Since the introduction of conjugated
pneumococcal vaccines (PCV) in infant immunization programs in 2000s, there is consistent evidence of pneumonia reduction in vaccinated
children1. Limited data are available on indirect effect of infant immunization on pneumonia burden in unvaccinated population subgroups2.
This study aims to assess indirect effect of infant PCV7/PCV13 vaccination on the pneumonia burden among 65+ years old (yo) in Portugal,
through comparison of trends in Pneumococcal Pneumonia (PP) hospitalization rates before and after the introduction of PCV7 and PCV13.
METHODS
RESULTS
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Using nationwide hospitalization registry data, we found a decrease in the PP hospitalization rates in 65+yo adults following infant
PCV7/PCV13 introduction in Portugal. The ageing of the population highlights the importance of this indirect effect on PP prevention. The
possibility of a pneumococcal serotype replacement reinforces the need for continuous monitoring of this health problem along time.
During the study period, the PP annual hospitalization rate varied between 10.2 and 4.0 per 104 inhabitants, being highest among 85+yo.
The decreasing trend continued after PCV13 introduction (RR=0.89;
CI95%: 0.86 to 0.91). The largest PP rate reduction was observed in
65–74yo, 14% per year (RR=0.86; CI95%: 0.79, 0.93) for men and
19% per year (RR=0.81; CI95%: 0.72, 0.92) for women, resulting
in 2.9 fewer hospitalizations per 104 inhabitants, in 2015/16.
Figure 1. Trends in monthly PP hospitalization rates before and after PCV7 / PCV13 introduction by sex and age group
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PP hospitalization rate increased in pre-PCV7 period in all population
subgroups. Statistically significant decline in PP rate was observed in
post-PCV7 period in 65–74yo women (RR=0.76, CI95%: 0.64; 0.90)
and 75–84yo men (RR=0.84, CI95%: 0.70; 0.99), resulting in 4.6
fewer hospitalizations per 104 inhabitants, in 2004/05.
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Study design: Ecological study based on the National Hospital
Discharge Registry data (July 1998 to June 2016). Target population
included individuals aged 65+yo resident in Portugal mainland.
Outcome: Hospitalizations (≥24 hours) with primary discharge diagnosis
of PP coded as 481/J13 International Statistical Classification of Diseases
Vaccination program settings:
𝑙𝑜𝑔𝐸 𝑌𝑡 = 𝛽0 + 𝛽1𝑇𝑡 + 𝛽2𝑋𝑡𝑇𝑡 + 𝛽3 sin 2𝜋𝑇𝑡/12 + 𝛽4 cos 2𝜋𝑇𝑡/12 + 𝛽5t𝐼𝐿𝐼𝑡 + log 𝑃𝑜𝑝𝑡 ,
Statistical analysis: Interrupted time series analysis. Poisson regression models adjusted for seasonality and influenza like illness (ILI)
were fitted separately for men and women for 65-74yo, 75-84yo and 85+yo age groups with a monthly count of PP hospitalizations (Yt) as
outcome variable:
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β0 - a baseline rate; Tt - time in months since the start of the study; Xt - a dummy variable representing the PCV use (0 in pre-PCV period, 1 otherwise); 
β1 - a slope in pre-PCV period; β2 - a change in the slope after PCV introduction.
